The debate surrounding cancer endpoints has focused on the issue of quality of life and progression. Panelists shared some of the challenges in assessing quality of life, since it can be a fickle and subjective process. The data can be hard to nail down since patients don’t always fill out the forms. The critical issues include survival rates, improved quality of life and progression of disease. Everything must be taken into consideration to determine endpoints, which is why the issue is hotly debated.
Subscribe to our e-newsletterVIEW OUR CURRENT ISSUE >
Tagsagriculture health Partnering BIOTECH patent FDA Greenhouse Gas Emission biotech industry Health Care biofuel biotechnology One-on-One's Events business development Biofuel Technology climate change healthcare BIO International Convention BIO Events renewable fuel standard
- Most Popular
Latest VideoHans Schikan, CEO of Prosensa, on Rare Disease Drug Development View All >